Cambridge Healthtech Institute’s 18th Annual
Advancing Multispecific Antibodies and Combination Therapy to the Clinic
Novel and Synergistic Combinations
18 November 2026
Cambridge Healthtech Institute's eighteenth-annual Advancing Multispecific Antibodies and Combination Therapy to the Clinic conference at PEGS Europe will present an overview of multispecific antibodies in preclinical and clinical development, with a review of current formats, designs, and clinical status. This field is experiencing rapid growth fueled by a wealth of format diversity and translation into clinical success. The field is moving from success in oncology to indications in autoimmune and beyond.
Coverage will include, but is not limited to:
- Optimising for developability
- Reviewing clinical progress of co-stimulatory mulitspecific antibodies
- Advancing novel immune-cell–engaging bispecific antibodies for oncology and autoimmune diseases
- Exploring learnings from the clinic for masked approaches
- Integrating co-stimulation in design of conditionally activated bi- and multispecifics
- Making multi-payload molecules
- Creating novel targeted internalizers and targeted degraders
The deadline for priority consideration is 9 April 2026.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: